Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.130
Neutral
RSI(14)
51.239
Neutral
STOCH(KDJ)(9,3,3)
43.920
Buy
ATR(14)
0.428
Low Volatility
CCI(14)
-10.585
Neutral
Williams %R
56.853
Sell
TRIX(12,20)
0.067
Sell
StochRSI(14)
86.618
Overbought
Valneva SE
VALN9.490USD
+0.160+1.71%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.54BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Valneva SE
Currency: USD Updated: 2026-02-06Key Insights
Valneva SE's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 105 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.71.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Valneva SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Valneva SE Highlights
StrengthsRisks
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Overvalued
The company’s latest PE is -8.57, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.28M shares, increasing 8.96% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.26.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
12.713
Target Price
+36.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Valneva SE is 7.23, ranking 138 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 25.51M, representing a year-over-year decrease of 44.32%, while its net profit experienced a year-over-year decrease of 316.62%.
Score
Financials
6.50
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.09
Operational Efficiency
10.00
Growth Potential
5.37
Shareholder Returns
7.19
Valneva SE's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Valneva SE is 7.18, ranking 157 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.57, which is -2174.36% below the recent high of 177.67 and -1275.82% above the recent low of -117.84.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 105/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Valneva SE is 8.50, ranking 105 out of 392 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 18.00 and a low of 7.55.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
12.713
Target Price
+36.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Valneva SE
VALN
4
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Valneva SE is 6.63, ranking 209 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.29 and the support level at 8.78, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
9.320
Buy
MA10
9.350
Buy
MA20
9.670
Sell
MA50
9.148
Buy
MA100
9.471
Buy
MA200
8.380
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Valneva SE is 3.63, ranking 131 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.83. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.83
VaR
--
240-Day Maximum Drawdown
+33.81%
240-Day Volatility
+70.72%
Return
Best Daily Return
60 days
+10.17%
120 days
+12.77%
5 years
--
Worst Daily Return
60 days
-5.42%
120 days
-18.99%
5 years
--
Sharpe Ratio
60 days
+0.94
120 days
-0.02
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+33.81%
3 years
+78.26%
5 years
--
Return-to-Drawdown Ratio
240 days
+0.64
3 years
-0.02
5 years
--
Skewness
240 days
+0.71
3 years
+0.89
5 years
--
Volatility
Realised Volatility
240 days
+70.72%
5 years
--
Standardised True Range
240 days
+4.27%
5 years
--
Downside Risk-Adjusted Return
120 days
-2.78%
240 days
-2.78%
Maximum Daily Upside Volatility
60 days
+49.51%
Maximum Daily Downside Volatility
60 days
+41.84%
Liquidity
Average Turnover Rate
60 days
+0.04%
120 days
+0.04%
5 years
--
Turnover Deviation
20 days
+325.77%
60 days
+101.96%
120 days
+106.43%
Peer Comparison
Biotechnology & Medical Research
Valneva SE
VALN
6.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
